UN Secretary-General Antonio Guterres on Friday lauded India’s role in the world as vaccine making hub. He applauded India for the supply of COVID-19 doses to countries around the world. India is called the pharmacy of the world and it is the world’s biggest makers of vaccines. Indian companies like Serum Institute of India and Bharat Biotech have played an instrumental role in manufacture COVID-19 vaccines. “I would like to say how much we count on India. I mean, India has one of the most advanced pharmaceutical industries. India played a very important role in the production of generics for use that was a very important element of democratisation of access to medicines all over the world,” Guterres said.

As United Nations Secretary-General Antonio Guterres hailed the vaccine production capacity of India as the “best asset” of the world, External Affairs Minister S Jaishankar said on Friday that the organisation can count on the ‘Pharmacy of the World’ to overcome the COVID-19 challenge. India, which is playing a major role in the global vaccination campaign, has gifted over 55 lakh doses of coronavirus vaccine to neighbouring countries. Emerging as a global pharmacy in times of health crisis, India plans to further gift vaccine doses to Oman, CARICOM countries, Nicaragua, and the Pacific Island states.

India has airlifted greater than 6 million COVID-19 doses to 9 nations in Part-I beneath its initiative termed “Vaccine Maitri”. Contractual provides to varied nations are additionally being undertaken in a phased method and New Delhi has stated it’s going to regularly provide to the COVAX facility of the World Well being Group.

COVAX is the worldwide initiative to make sure fast and equitable entry to COVID-19 vaccines for all nations, no matter earnings degree. COVAX is the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level. This month, COVAX had announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in the first quarter of 2021, via existing agreements with the Serum Institute of India (SII) and AstraZeneca.